SML1265
波生坦 水合物
≥98% (HPLC), endothelin receptor antagonist, powder
别名:
4-(1,1-二甲基乙基)-N-[6-(2-羟基乙氧基)-5-(2-甲氧基苯氧基)[2,2′-联嘧啶]-4-基]-苯磺酰胺 一水合物, 4-叔丁基-N- [6-(2-羟基乙氧基)-5-(2-甲氧基-苯氧基)-[2,2´]-联嘧啶-4-基]-苯磺酰胺 一水合物, Ro-47-0203
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C27H29N5O6S · H2O
化学文摘社编号:
分子量:
569.63
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
波生坦 水合物, ≥98% (HPLC)
SMILES string
O=S(C1=CC=C(C(C)(C)C)C=C1)(NC2=NC(C3=NC=CC=N3)=NC(OCCO)=C2OC4=CC=CC=C4OC)=O.O
InChI
1S/C27H29N5O6S.H2O/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24;/h5-15,33H,16-17H2,1-4H3,(H,30,31,32);1H2
InChI key
SXTRWVVIEPWAKM-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
2-8°C
Quality Level
相关类别
Application
水合波生坦已用于细胞活力测定。此外，它还被用作钙瞬态分析的阳性对照。
Biochem/physiol Actions
已有发现证明，波生坦可减少肺中胶原蛋白沉积——在博来霉素诱导的肺纤维化大鼠模型中观察到此现象。
波生坦是一种内皮素受体拮抗剂。内皮素是一种有效的血管收缩药，因而成为治疗血管痉挛相关疾病（如蛛网膜下腔出血 (SAH) 和高血压）的临床关注拮抗剂。波生坦是一种双重内皮素受体拮抗剂，可有效治疗肺动脉高压(PAH)，这是首个投放市场的同类产品。波生坦是 ETA 和 ETB 受体亚型（ETA 的 Ki 为4.7 nM，ETB 的 Ki为95 nM）的竞争性口服拮抗剂。
波生坦是一种内皮素受体拮抗剂；降压；肺动脉高压治疗。
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 3 - Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Molecular phenotyping combines molecular information, biological relevance, and patient data to improve productivity of early drug discovery.
Drawnel F M, et al.
Cell Chemical Biology, 24(5), 624-634 (2017)
Xiaomin Liang et al.
Drug metabolism and disposition: the biological fate of chemicals, 48(12), 1283-1292 (2020-10-11)
It is well documented that human hepatic clearance based on in vitro metabolism or transporter assays systematically resulted in underprediction; therefore, large empirical scalars are often needed in either static or physiologically based pharmacokinetic (PBPK) models to accurately predict human
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Russignan A, et al.
British Journal of Haematology, 178(5), 781-793 (2017)
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
King Jr T E, et al.
American Journal of Respiratory and Critical Care Medicine, 177(1), 75-81 (2008)
Mona Bensalah et al.
Journal of cachexia, sarcopenia and muscle, 13(3), 1771-1784 (2022-03-24)
Fibrosis is defined as an excessive accumulation of extracellular matrix (ECM) components. Many organs are subjected to fibrosis including the lung, liver, heart, skin, kidney, and muscle. Muscle fibrosis occurs in response to trauma, aging, or dystrophies and impairs muscle
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持